search
Back to results

Effect of Blueberry Supplementation on Alzheimer's Biomarkers

Primary Purpose

Mild Cognitive Impairment, Alzheimer Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
lyophilized blueberry supplement
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Mild Cognitive Impairment focused on measuring MCI, biomarkers, memory loss

Eligibility Criteria

55 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 55 to 85 years old inclusive
  2. Meets criteria for amnestic Mild Cognitive Impairment defined by education adjusted performance on the Wechsler Memory Scale (WMS) III Logical Memory delayed recall score and clinical evaluation.
  3. Medically stable

Exclusion Criteria:

  1. Dementia
  2. Significant confounding active neurological/psychiatric disease
  3. Participation in an experimental investigational drug trial in the past 30 days
  4. Unwilling to restrict consumption of anthocyanin-rich foods
  5. Inability to complete cognitive testing (e.g. significant visual or hearing impairment)
  6. Allergy or intolerance to blueberries
  7. Significant gastrointestinal disorders or surgery that influences digestion and absorption
  8. Presence of unstable, acutely symptomatic, or life-limiting illness
  9. Women of childbearing potential

Sites / Locations

  • Duke University Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Blueberry supplementation

Arm Description

All participants will receive 18 grams lyophilized blueberry supplement mixed with water twice daily for 12 weeks.

Outcomes

Primary Outcome Measures

Change in blood Neurofilament light (NfL) levels as measured by blood biomarker assay
Change in blood glial fibrillary acidic protein (GFAP) levels as measured by blood biomarker assay
Change in blood Amyloid beta 40/42 as measured by blood biomarker assay
Change in p-tau 181 as measured by blood biomarker assay
Change in blood interleukin-6 (IL-6) levels as measured by blood biomarker assay
Change in tumor necrosis factor (TNF-alpha) levels as measured by blood biomarker assay
Change in brain-derived neurotrophic factor (BDNF)

Secondary Outcome Measures

Full Information

First Posted
December 9, 2021
Last Updated
March 7, 2023
Sponsor
Duke University
Collaborators
U.S. Highbush Blueberry Council
search

1. Study Identification

Unique Protocol Identification Number
NCT05172128
Brief Title
Effect of Blueberry Supplementation on Alzheimer's Biomarkers
Official Title
Effect of Blueberry Supplementation on Alzheimer's Biomarkers
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
February 21, 2022 (Actual)
Primary Completion Date
February 6, 2023 (Actual)
Study Completion Date
February 6, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
Collaborators
U.S. Highbush Blueberry Council

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to study the effects of blueberries on neuronal, glial, and pathology blood biomarkers in Mild Cognitive Impairment (MCI) and to estimate sample size for future confirmatory studies. The blood biomarkers to be measured are Neurofilament light (NfL), glial fibrillary acidic protein (GFAP), Aß40, Aß42, p-tau181, and cytokines, using an ultra-sensitive state-of-the-art immunoassay.
Detailed Description
After determining subject eligibility and after subjects have abstained from consuming all berry fruits (including red wine) for 2 weeks, subjects will have blood drawn for biomarkers and will then will undergo 12 weeks of blueberry supplementation in the form of 18 grams lyophilized blueberry powder mixed with water and taken twice daily with meals. All subjects will be asked to abstain from berry fruits (including red wine) for the duration of the 12 week trial. Subjects will receive telephone calls at 4 and 8 weeks to check compliance as well as concomitant medications and adverse events and then all subjects will return at 12 weeks for a repeat biomarker blood draw. Plasma NfL, GFAP, Aβ40, Aβ42, p-tau181, and cytokine biomarker assays will be done using the Quanterix SR-X instrument, a new, state-of-the-art digital immunoassay platform employing Simoa technology, which enables the detection and quantification of biomarkers previously difficult or impossible to measure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild Cognitive Impairment, Alzheimer Disease
Keywords
MCI, biomarkers, memory loss

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Blueberry supplementation
Arm Type
Experimental
Arm Description
All participants will receive 18 grams lyophilized blueberry supplement mixed with water twice daily for 12 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
lyophilized blueberry supplement
Intervention Description
lyophilized blueberry supplement bid
Primary Outcome Measure Information:
Title
Change in blood Neurofilament light (NfL) levels as measured by blood biomarker assay
Time Frame
Baseline, 12 weeks
Title
Change in blood glial fibrillary acidic protein (GFAP) levels as measured by blood biomarker assay
Time Frame
Baseline, 12 weeks
Title
Change in blood Amyloid beta 40/42 as measured by blood biomarker assay
Time Frame
Baseline, 12 weeks
Title
Change in p-tau 181 as measured by blood biomarker assay
Time Frame
Baseline, 12 weeks
Title
Change in blood interleukin-6 (IL-6) levels as measured by blood biomarker assay
Time Frame
Baseline, 12 weeks
Title
Change in tumor necrosis factor (TNF-alpha) levels as measured by blood biomarker assay
Time Frame
Baseline, 12 weeks
Title
Change in brain-derived neurotrophic factor (BDNF)
Time Frame
Baseline, 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 55 to 85 years old inclusive Meets criteria for amnestic Mild Cognitive Impairment defined by education adjusted performance on the Wechsler Memory Scale (WMS) III Logical Memory delayed recall score and clinical evaluation. Medically stable Exclusion Criteria: Dementia Significant confounding active neurological/psychiatric disease Participation in an experimental investigational drug trial in the past 30 days Unwilling to restrict consumption of anthocyanin-rich foods Inability to complete cognitive testing (e.g. significant visual or hearing impairment) Allergy or intolerance to blueberries Significant gastrointestinal disorders or surgery that influences digestion and absorption Presence of unstable, acutely symptomatic, or life-limiting illness Women of childbearing potential
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Murali Doraiswamy, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28283823
Citation
Miller MG, Hamilton DA, Joseph JA, Shukitt-Hale B. Dietary blueberry improves cognition among older adults in a randomized, double-blind, placebo-controlled trial. Eur J Nutr. 2018 Apr;57(3):1169-1180. doi: 10.1007/s00394-017-1400-8. Epub 2017 Mar 10.
Results Reference
background
PubMed Identifier
26606074
Citation
Wang S, Cui Y, Wang C, Xie W, Ma L, Zhu J, Zhang Y, Dang R, Wang D, Wu Y, Wu Q. Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's Disease. PLoS One. 2015 Nov 25;10(11):e0143135. doi: 10.1371/journal.pone.0143135. eCollection 2015. Erratum In: PLoS One. 2015;10(12):e0146252. Cu, Yu [corrected to Cui, Yu].
Results Reference
background
PubMed Identifier
24117094
Citation
Jeong HR, Jo YN, Jeong JH, Kim HJ, Kim MJ, Heo HJ. Blueberry (Vaccinium virgatum) leaf extracts protect against Abeta-induced cytotoxicity and cognitive impairment. J Med Food. 2013 Nov;16(11):968-76. doi: 10.1089/jmf.2013.2881. Epub 2013 Oct 11.
Results Reference
background
PubMed Identifier
19954954
Citation
Brewer GJ, Torricelli JR, Lindsey AL, Kunz EZ, Neuman A, Fisher DR, Joseph JA. Age-related toxicity of amyloid-beta associated with increased pERK and pCREB in primary hippocampal neurons: reversal by blueberry extract. J Nutr Biochem. 2010 Oct;21(10):991-8. doi: 10.1016/j.jnutbio.2009.08.005. Epub 2009 Dec 1.
Results Reference
background
Citation
Ou Y, Hu H, Wang Z, Xu W, Tan L, et al. Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's disease. Brain Science Advances. 2019;5(2):94-105.
Results Reference
background

Learn more about this trial

Effect of Blueberry Supplementation on Alzheimer's Biomarkers

We'll reach out to this number within 24 hrs